查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1412263

胃轻瘫药物市场：按药物类别、适应症、销售管道划分 - 全球预测 2024-2030 年

Gastroparesis Drugs Market by Drug Class (Anti-Emetic Agents, Botulinum Toxin Injections, Prokinetic Agents), Indication (Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis), Sales Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年胃轻瘫药物市场规模为43.7亿美元，2024年达45.4亿美元，预计2030年将达到68.5亿美元，复合年增长率为6.61%。

全球胃轻瘫药物市场

主要市场统计
基准年[2023] 43.7亿美元
预测年份 [2024] 45.4亿美元
预测年份 [2030] 68.5亿美元
复合年增长率（%） 6.61%
胃轻瘫治疗药物市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估胃轻瘫药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出资讯的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对胃轻瘫药物市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵考察，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更资讯的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-胃轻瘫治疗药物市场的市场规模与预测是多少？

2-胃轻瘫药物市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些？

3-胃轻瘫药物市场的技术趋势和法律规范是什么？

4-胃轻瘫药物市场主要供应商的市场占有率为何？

5-进入胃轻瘫药物市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地患有糖尿病的人数正在增加。
      • 增加对医疗基础设施的投资，以改善获得医疗服务的机会
    • 抑制因素
      • 降血脂药物製剂所用原料价格昂贵。
    • 机会
      • 开发新药的持续研究和开发活动
      • 全球监管机构核准的药品数量增加
    • 任务
      • 服用胃轻瘫治疗药物相关的严重副作用
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章依药物类别分類的胃轻瘫治疗药物市场

  • 止吐药
  • 肉毒毒素注射
  • 运动促进者

第七章胃轻瘫治疗药物市场（依适应症）

  • 糖尿病性胃轻瘫
  • 特发性胃轻瘫
  • 术后胃轻瘫

第八章胃轻瘫治疗药物市场：依销售管道

  • 离线
    • 医院药房
    • 零售药房
  • 在线的

第九章 北美及南美胃轻瘫药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太胃轻瘫药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东与非洲胃轻瘫药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第13章竞争产品组合

  • 主要公司简介
    • Abbott Laboratories
    • AbbVie Inc.
    • Amneal Pharmaceuticals, Inc.
    • ANI Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Atlantic Healthcare PLC
    • Bausch Health Companies Inc.
    • Bristol-Myers Squibb Company
    • Cadila Pharmaceuticals Limited
    • Cairn Diagnostics
    • Evoke Pharma, Inc.
    • GlaxoSmithKline PLC
    • Johnson & Johnson Services, Inc.
    • Kyowa Kirin International plc
    • Lupin Limited
    • Medtronic PLC
    • Neurogastrx, Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Processa Pharmaceuticals, Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Theravance Biopharma
    • Vanda Pharmaceuticals Inc.
    • Viatris Inc.
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-C002B1C99722

[199 Pages Report] The Gastroparesis Drugs Market size was estimated at USD 4.37 billion in 2023 and expected to reach USD 4.54 billion in 2024, at a CAGR 6.61% to reach USD 6.85 billion by 2030.

Global Gastroparesis Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 4.37 billion
Estimated Year [2024] USD 4.54 billion
Forecast Year [2030] USD 6.85 billion
CAGR (%) 6.61%
Gastroparesis Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Gastroparesis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Gastroparesis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Gastroparesis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amneal Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., AstraZeneca PLC, Atlantic Healthcare PLC, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Cairn Diagnostics, Evoke Pharma, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Kyowa Kirin International plc, Lupin Limited, Medtronic PLC, Neurogastrx, Inc., Novartis AG, Pfizer, Inc., Processa Pharmaceuticals, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Theravance Biopharma, Vanda Pharmaceuticals Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Gastroparesis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Anti-Emetic Agents
    • Botulinum Toxin Injections
    • Prokinetic Agents
  • Indication
    • Diabetic Gastroparesis
    • Idiopathic Gastroparesis
    • Post-surgical Gastroparesis
  • Sales Channel
    • Offline
      • Hospitals Pharmacies
      • Retail Pharmacies
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Gastroparesis Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Gastroparesis Drugs Market?

3. What are the technology trends and regulatory frameworks in the Gastroparesis Drugs Market?

4. What is the market share of the leading vendors in the Gastroparesis Drugs Market?

5. Which modes and strategic moves are suitable for entering the Gastroparesis Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Gastroparesis Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in diabetic population across the globe
      • 5.1.1.2. Rising investment in healthcare infrastructure to enhance healthcare accessibility
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of raw materials used in formulation of hyperlipidemia drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous research & development activities for new drug development
      • 5.1.3.2. Increasing drug approvals by the regulatory authorities worldwide
    • 5.1.4. Challenges
      • 5.1.4.1. Severe side effects associated with the consumption of gastroparesis drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Gastroparesis Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-Emetic Agents
  • 6.3. Botulinum Toxin Injections
  • 6.4. Prokinetic Agents

7. Gastroparesis Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Diabetic Gastroparesis
  • 7.3. Idiopathic Gastroparesis
  • 7.4. Post-surgical Gastroparesis

8. Gastroparesis Drugs Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Offline
    • 8.3.1. Hospitals Pharmacies
    • 8.3.2. Retail Pharmacies
  • 8.3. Online

9. Americas Gastroparesis Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gastroparesis Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gastroparesis Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. AbbVie Inc.
    • 13.1.3. Amneal Pharmaceuticals, Inc.
    • 13.1.4. ANI Pharmaceuticals, Inc.
    • 13.1.5. AstraZeneca PLC
    • 13.1.6. Atlantic Healthcare PLC
    • 13.1.7. Bausch Health Companies Inc.
    • 13.1.8. Bristol-Myers Squibb Company
    • 13.1.9. Cadila Pharmaceuticals Limited
    • 13.1.10. Cairn Diagnostics
    • 13.1.11. Evoke Pharma, Inc.
    • 13.1.12. GlaxoSmithKline PLC
    • 13.1.13. Johnson & Johnson Services, Inc.
    • 13.1.14. Kyowa Kirin International plc
    • 13.1.15. Lupin Limited
    • 13.1.16. Medtronic PLC
    • 13.1.17. Neurogastrx, Inc.
    • 13.1.18. Novartis AG
    • 13.1.19. Pfizer, Inc.
    • 13.1.20. Processa Pharmaceuticals, Inc.
    • 13.1.21. Sanofi S.A.
    • 13.1.22. Takeda Pharmaceutical Company Limited
    • 13.1.23. Theravance Biopharma
    • 13.1.24. Vanda Pharmaceuticals Inc.
    • 13.1.25. Viatris Inc.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. GASTROPARESIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GASTROPARESIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GASTROPARESIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GASTROPARESIS DRUGS MARKET DYNAMICS
  • FIGURE 7. GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. GASTROPARESIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GASTROPARESIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 6. GASTROPARESIS DRUGS MARKET SIZE, BY ANTI-EMETIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GASTROPARESIS DRUGS MARKET SIZE, BY BOTULINUM TOXIN INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GASTROPARESIS DRUGS MARKET SIZE, BY PROKINETIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 10. GASTROPARESIS DRUGS MARKET SIZE, BY DIABETIC GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GASTROPARESIS DRUGS MARKET SIZE, BY IDIOPATHIC GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GASTROPARESIS DRUGS MARKET SIZE, BY POST-SURGICAL GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 16. GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 187. GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 188. GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. GASTROPARESIS DRUGS MARKET LICENSE & PRICING